20 articles
JAMA publishes a timely review of IgA nephropathy, the leading cause of primary glomerulonephritis worldwide, amid a wave of new therapies.
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
Whole genome sequencing of 7,339 Chinese participants uncovers novel genetic variants affecting serum uric acid, opening doors for precision therapies.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
New research identifies Lp-PLA2 enzyme as therapeutic target for deadly lung disease affecting millions of workers worldwide.
Nephrologists from Canada and Ireland address clinical questions on IgA nephropathy, one of the most common causes of kidney failure worldwide.
Demethyleneberberine, derived from traditional Chinese medicine, significantly reduced lung scarring by targeting NLRP3 inflammasome and EMT in mice.
Phase I trial tests selective JAK3 inhibitor with improved safety profile compared to existing treatments for inflammatory conditions.
Breakthrough therapy targeting B cells demonstrates significant improvement in lupus symptoms with sustained benefits over one year.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
Daratumumab monotherapy showed promising results in treating refractory lupus nephritis by reducing inflammation and fibrosis.
Scientists develop potent ฮฑ5ฮฒ1 integrin inhibitor for inhalation therapy, offering new approach for severe asthma patients.
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
New research identifies key factors behind difficult-to-treat RA and highlights JAK inhibitors as promising therapy option.
Phase 2 trial tests novel therapy for patients who failed standard biologics and JAK inhibitors in 145-person study.
New research reveals E. coli dominates and suppresses S. aureus in dual-species implant biofilms, with major implications for treating polymicrobial joint infections.
A completed Phase II trial tested the checkpoint inhibitor ASC22 alongside antiretroviral therapy to target HIV-1 immune exhaustion.
Researchers develop standardized lung washing procedure that rapidly improves breathing and quality of life in patients with rare disease.
Researchers uncover how the STING immune pathway triggers mitochondrial fragmentation and DNA release, fueling deadly lung inflammation in sepsis.
New AI tool provides personalized, accessible information for lupus patients, improving disease understanding and care.
